We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
-$174M
Cap. Flow
-$47.6M
Cap. Flow %
-4.51%
Top 10 Hldgs %
100%
Holding
8
New
3
Increased
2
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$177M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$57.1M
3
VRNA
Verona Pharma
VRNA
+$30.4M
4
KROS icon
Keros Therapeutics
KROS
+$8.49M
5
NRIX icon
Nurix Therapeutics
NRIX
+$3.75M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$251M
2
GERN icon
Geron
GERN
+$49.8M
3
SMMT icon
Summit Therapeutics
SMMT
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.5B
$895M 84.75%
12,960,538
+2,463,261
+23% +$177M
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$15.5B
$59.7M 5.65%
+484,515
New +$57.1M
VRNA
3
DELISTED
Verona Pharma
VRNA
$37.6M 3.56%
+810,449
New +$30.4M
GERN icon
4
Geron
GERN
$924M
$33.9M 3.21%
9,569,835
-12,468,938
-57% -$49.8M
KROS icon
5
Keros Therapeutics
KROS
$211M
$26.7M 2.53%
1,687,135
+163,403
+11% +$8.49M
NRIX icon
6
Nurix Therapeutics
NRIX
$2.4B
$3.08M 0.29%
+163,681
New +$3.75M
PCVX icon
7
Vaxcyte
PCVX
$8.12B
– –
-2,198,187
Closed -$251M
SMMT icon
8
Summit Therapeutics
SMMT
$10.7B
– –
-1,084,880
Closed -$23.8M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q4 2024 Portfolio in Review

As of Q4 2024, Darwin Global Management held 8 positions worth $1.06B, down 14% from $1.23B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management withdrew a net $47.6M in Q4 2024, closing 2 positions and reducing 1 holding. Its most notable exit was Vaxcyte, an estimated $251M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Darwin Global Management opened a new position in Jazz Pharmaceuticals worth $59.7M.

  • Darwin Global Management's largest Q4 2024 buy was Jazz Pharmaceuticals: 484,515 shares worth $59.7M.
  • Darwin Global Management added most to Insmed in Q4 2024, an estimated $177M increase.
  • Darwin Global Management's biggest Q4 2024 reduction was Geron, cutting an estimated $49.8M.
  • Darwin Global Management fully exited Vaxcyte in Q4 2024, selling an estimated $251M.
  • Darwin Global Management's ten largest holdings make up 100% of its $1.06B portfolio in Q4 2024.
  • Darwin Global Management opened 3 new positions and closed 2 in Q4 2024.
  • Darwin Global Management's portfolio value fell 14% quarter-over-quarter to $1.06B.

Based on Darwin Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.